Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
12.6
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSNet Sales4,764¥ millionYear on year +12.6%Progress 14.9%
Operating profit-1,140¥ million
Ordinary income-1,202¥ million (IFRS profit before tax)
Net income attributable to owners of the parent-854¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥6.62
Financial position at period-end
Total assets74,696¥ million
of which net assets 49,747 ¥ millionEquity ratio 66.6%vs. prior year-end -0.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-945,684
Investment-319,752
Financials-1,900,318
Net change-3,165,754
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥25,550,978 thousand
Segment revenueDrug discovery and development business ¥670,287 thousand, Radiopharmaceutical Business ¥4,094,671 thousand
Segment profitDrug discovery and development business -1,192,597 Thousands of yen (segment loss), Radiopharmaceutical Business 74,553 Thousands of yen (segment profit)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥32,000 million (YoY +72.8%)
Operating profit¥4,600 million
Ordinary income¥4,300 million (IFRS profit before tax)
Net income¥3,000 million
Annual Dividend Forecast¥0 → ¥0（0.0%）
Factors Behind Changes in Business Performance
No specific causal factors were provided. The drug discovery and development business recorded a ¥263,178 thousand increase in revenue and a ¥235,780 thousand reduction in segment loss, while the radiopharmaceutical business recorded a ¥268,533 thousand increase in revenue and a ¥8,957 thousand decrease in segment profit.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationAdded: 0 companies; excluded: 0 companies. There were no material changes to the scope of consolidation during the period.
Impairment lossNone recorded. Impairment losses on property, plant and equipment, intangible assets and goodwill were all “—”.
Breakdown of extraordinary income (loss)No breakdown of extraordinary income or loss was provided. All adjustment items for Core operating profit, including “non-recurring and material gains or losses,” were “—”.
Depreciation and amortization¥542,450 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End130,010,400
Treasury Shares at Period-End1,518,035
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥4,764 million (YoY +12.6%) |
| Operating profit | ¥-1,140 million |
| Ordinary income | ¥-1,202 million (IFRS profit before tax) |
| Profit attributable to owners of the parent | ¥-854 million |
| Net income per share | -¥6.62 |
| Equity ratio | End of the current fiscal period 66.6 / End of previous period 66.9 |
| Total assets | ¥74,696 million |
| Net assets | ¥49,747 million |
| Cash flows from operating activities | ¥-945,684 thousand |
| Cash flows from investing activities | ¥-319,752 thousand |
| Cash flows from financing activities | ¥-1,900,318 thousand |
| Cash and cash equivalents at end of period | ¥25,550,978 thousand |
| Full-year earnings forecast | Net Sales ¥32,000 million (YoY +72.8%) / Operating profit ¥4,600 million / Ordinary income ¥4,300 million (IFRS profit before tax) / Net income ¥3,000 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Drug discovery and development business ¥670,287 thousand, Radiopharmaceutical Business ¥4,094,671 thousand |
| Segment profit | Drug discovery and development business -1,192,597 Thousands of yen (segment loss), Radiopharmaceutical Business 74,553 Thousands of yen (segment profit) |
| Depreciation and amortization | ¥542,450 thousand |
| Impairment loss | None recorded. Impairment losses on property, plant and equipment, intangible assets and goodwill were all “—”. |
| Breakdown of extraordinary income (loss) | No breakdown of extraordinary income or loss was provided. All adjustment items for Core operating profit, including “non-recurring and material gains or losses,” were “—”. |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies. There were no material changes to the scope of consolidation during the period. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 130,010,400 |
| Treasury Shares at Period-End | 1,518,035 |
| Factors Behind Changes in Business Performance | No specific causal factors were provided. The drug discovery and development business recorded a ¥263,178 thousand increase in revenue and a ¥235,780 thousand reduction in segment loss, while the radiopharmaceutical business recorded a ¥268,533 thousand increase in revenue and a ¥8,957 thousand decrease in segment profit. |
Items this document does not state (7)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company did not provide specific reasons for the changes in performance, but reported the changes in revenue and segment profit or loss for the drug discovery and development business and radiopharmaceutical business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.